SCHEMBL474175

SCHEMBL474175

Nc1nc(-c2cc(Cl)c(OC(F)F)c(Cl)c2)cs1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 3/20 0.44
ALDH1A1 P00352 10/20 0.42
RAB9A P51151 9/20 0.42
ALOX5 P09917 1/20 0.42
MAPT P10636 7/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
KDM4E B2RXH2 4/20 0.42
NPC1 O15118 7/20 0.40
SMN1; SMN2 Q16637 6/20 0.40
NFKB1 P19838 2/20 0.40
NFKB2 Q00653 2/20 0.40
RELA Q04206 2/20 0.40
POLB P06746 1/20 0.40
AR P10275 1/20 0.40
GFER P55789 1/20 0.40
LMNA P02545 1/20 0.39
MKNK1 Q9BUB5 1/20 0.39
MKNK2 Q9HBH9 1/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL474167 0.83 ALDH1A1 (0.51) LTA4HALDH1A1RAB9AALOX5MAPT
SCHEMBL474887 0.81 ALDH1A1 (0.53) LTA4HALDH1A1RAB9AALOX5MAPT
SCHEMBL17400558 0.80 ALDH1A1 (0.54) LTA4HALDH1A1RAB9AALOX5MAPT
SCHEMBL16003852 0.77 ALDH1A1 (0.58) LTA4HALDH1A1RAB9AALOX5MAPT
SCHEMBL473573 0.75 TRPA1 (0.43) LTA4HALDH1A1RAB9AALOX5MAPT
SCHEMBL474221 0.75 MPL (0.45) LTA4HALDH1A1RAB9AALOX5MAPT
SCHEMBL17407201 0.74 ALDH1A1 (0.48) LTA4HALDH1A1RAB9AALOX5MAPT
SCHEMBL2444321 0.73 TRPA1 (0.45) LTA4HALDH1A1RAB9AALOX5MAPT
SCHEMBL10340168 0.73 ALDH1A1 (0.63) LTA4HALDH1A1RAB9AALOX5MAPT
SCHEMBL14910191 0.73 MAPT (0.33) MAPTSMN1; SMN2LMNAHPGDTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411395-B1 FUROPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS SA (CH) 2013-05-29 EP disclosed
US-20120178766-A1 FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2012-07-12 US disclosed
US-20120178766-A1 FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2012-07-12 US disclosed
US-20120178766-A1 FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2012-07-12 US disclosed
EP-2411395-A1 FUROPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS Glenmark Pharmaceuticals S.A. (CH) 2012-02-01 EP disclosed
WO-2010109329-A1 FUROPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2010-09-30 WO disclosed
WO-2010109329-A1 FUROPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178766-A1 FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS TRPA1, TRPV1, TRPC3 LTA4H 234/4885ALDH1A1 449/4885RAB9A 2462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.